EGFR and EGFRvIII expression in primary breast cancer and cell lines

James M. Rae, Joshua O. Scheys, Kim M. Clark, Robert B. Chadwick, Michael C. Kiefer, Marc E. Lippman

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


EGFRvIII is a constitutively activated truncated variant of the epidermal growth factor receptor (EGFR) which has been shown to increase tumorgenicity. There are conflicting reports on the extent of EGFRvIII expression in tissues which may in part stem from the use of different assay methodologies. We investigated the expression of both EGFRvIII and wild-type EGFR (EGFRwt) in cell lines and primary breast cancers. First, we used a RT-PCR assay that can simultaneously measure EGFRwt and EGFRvIII mRNA to screen 55 tumor cell lines. We show that except for EGFRvIII transfected cells, only EGFRwt was detected. We then validated a real-time PCR assay and used this to screen 170 formalin fixed paraffin-embedded primary breast cancers for evidence of EGFRwt and EGFRvIII expression. No samples were positive for EGFRvIII expression except for control transfectants and glioblastomas. In contrast, EGFRwt was expressed at varying levels in the majority of samples tested. We conclude that the expression of EGFRvIII is extremely rare in breast cancer and therefore it does not contribute to the malignant phenotype.

Original languageEnglish (US)
Pages (from-to)87-95
Number of pages9
JournalBreast cancer research and treatment
Issue number1
StatePublished - Sep 2004
Externally publishedYes


  • breast cancer
  • clinical
  • epidermal growth factor receptor
  • expression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'EGFR and EGFRvIII expression in primary breast cancer and cell lines'. Together they form a unique fingerprint.

Cite this